278 related articles for article (PubMed ID: 19622019)
41. Characterization of nickel-decorated PLGA particles anchored with a his-tagged polycation.
Kovacs JR; Tidball J; Ross A; Jia L; Zheng Y; Gawalt ES; Meng WS
J Biomater Sci Polym Ed; 2009; 20(9):1307-20. PubMed ID: 19520014
[TBL] [Abstract][Full Text] [Related]
42. Tumor eradication by immunotherapy with biodegradable PLGA microspheres--an alternative to incomplete Freund's adjuvant.
Mueller M; Schlosser E; Gander B; Groettrup M
Int J Cancer; 2011 Jul; 129(2):407-16. PubMed ID: 21207410
[TBL] [Abstract][Full Text] [Related]
43. Toll-like receptor-9 expression induced by tape-stripping triggers on effective immune response with CpG-oligodeoxynucleotides.
Inoue J; Aramaki Y
Vaccine; 2007 Jan; 25(6):1007-13. PubMed ID: 17049678
[TBL] [Abstract][Full Text] [Related]
44. The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting.
Chung YI; Kim JC; Kim YH; Tae G; Lee SY; Kim K; Kwon IC
J Control Release; 2010 May; 143(3):374-82. PubMed ID: 20109508
[TBL] [Abstract][Full Text] [Related]
45. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.
Mata E; Carcaboso AM; Hernández RM; Igartua M; Corradin G; Pedraz JL
Vaccine; 2007 Jan; 25(5):877-85. PubMed ID: 17070628
[TBL] [Abstract][Full Text] [Related]
46. Incorporation of CpG oligonucleotide ligand into protein-loaded particle vaccines promotes antigen-specific CD8 T-cell immunity.
Standley SM; Mende I; Goh SL; Kwon YJ; Beaudette TT; Engleman EG; Fréchet JM
Bioconjug Chem; 2007; 18(1):77-83. PubMed ID: 17226959
[TBL] [Abstract][Full Text] [Related]
47. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles.
Martínez Gómez JM; Fischer S; Csaba N; Kündig TM; Merkle HP; Gander B; Johansen P
Pharm Res; 2007 Oct; 24(10):1927-35. PubMed ID: 17541735
[TBL] [Abstract][Full Text] [Related]
48. The effect of poly(D,L-lactide-co-glycolide) microparticles with polyelectrolyte self-assembled multilayer surfaces on the cross-presentation of exogenous antigens.
Yang YW; Hsu PY
Biomaterials; 2008 Jun; 29(16):2516-26. PubMed ID: 18329708
[TBL] [Abstract][Full Text] [Related]
49. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).
Weeratna RD; Makinen SR; McCluskie MJ; Davis HL
Vaccine; 2005 Nov; 23(45):5263-70. PubMed ID: 16081189
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles.
Borges O; Tavares J; de Sousa A; Borchard G; Junginger HE; Cordeiro-da-Silva A
Eur J Pharm Sci; 2007 Dec; 32(4-5):278-90. PubMed ID: 17884394
[TBL] [Abstract][Full Text] [Related]
51. Induction of antigen-specific cytotoxic T lymphocytes by immunization with negatively charged soluble antigen through scavenger receptor-mediated delivery.
Yamasaki Y; Ikenaga T; Otsuki T; Nishikawa M; Takakura Y
Vaccine; 2007 Jan; 25(1):85-91. PubMed ID: 16956699
[TBL] [Abstract][Full Text] [Related]
52. Oral nuclear factor-κB decoy oligonucleotides delivery system with chitosan modified poly(D,L-lactide-co-glycolide) nanospheres for inflammatory bowel disease.
Tahara K; Samura S; Tsuji K; Yamamoto H; Tsukada Y; Bando Y; Tsujimoto H; Morishita R; Kawashima Y
Biomaterials; 2011 Jan; 32(3):870-8. PubMed ID: 20934748
[TBL] [Abstract][Full Text] [Related]
53. Encapsulation of Aβ(1-15) in PLGA microparticles enhances serum antibody response in mice immunized by subcutaneous and intranasal routes.
Puras G; Salvador A; Igartua M; Hernández RM; Pedraz JL
Eur J Pharm Sci; 2011 Oct; 44(3):200-6. PubMed ID: 21820509
[TBL] [Abstract][Full Text] [Related]
54. Activation of Antigen-Specific CD8(+) T Cells by Poly-DL-Lactide/Glycolide (PLGA) Nanoparticle-Primed Gr-1(high) Cells.
Luo WH; Yang YW
Pharm Res; 2016 Apr; 33(4):942-55. PubMed ID: 26715415
[TBL] [Abstract][Full Text] [Related]
55. Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses.
Thomas C; Gupta V; Ahsan F
Int J Pharm; 2009 Sep; 379(1):41-50. PubMed ID: 19524654
[TBL] [Abstract][Full Text] [Related]
56. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity.
Pawar D; Mangal S; Goswami R; Jaganathan KS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):550-9. PubMed ID: 23831265
[TBL] [Abstract][Full Text] [Related]
57. Enhancing immunogenicity to PLGA microparticulate systems by incorporation of alginate and RGD-modified alginate.
Mata E; Igartua M; Patarroyo ME; Pedraz JL; Hernández RM
Eur J Pharm Sci; 2011 Sep; 44(1-2):32-40. PubMed ID: 21699977
[TBL] [Abstract][Full Text] [Related]
58. Enhanced cellular association of paclitaxel delivered in chitosan-PLGA particles.
Chakravarthi SS; Robinson DH
Int J Pharm; 2011 May; 409(1-2):111-20. PubMed ID: 21356285
[TBL] [Abstract][Full Text] [Related]
59. Immune responses to vaccines delivered by encapsulation into and/or adsorption onto cationic lipid-PLGA hybrid nanoparticles.
Liu L; Ma P; Wang H; Zhang C; Sun H; Wang C; Song C; Leng X; Kong D; Ma G
J Control Release; 2016 Mar; 225():230-9. PubMed ID: 26826307
[TBL] [Abstract][Full Text] [Related]
60. Biodegradable particles as vaccine delivery systems: size matters.
Joshi VB; Geary SM; Salem AK
AAPS J; 2013 Jan; 15(1):85-94. PubMed ID: 23054976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
